[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IS4518A - Nýtt lyfjaform fyrir bóluefni - Google Patents

Nýtt lyfjaform fyrir bóluefni

Info

Publication number
IS4518A
IS4518A IS4518A IS4518A IS4518A IS 4518 A IS4518 A IS 4518A IS 4518 A IS4518 A IS 4518A IS 4518 A IS4518 A IS 4518A IS 4518 A IS4518 A IS 4518A
Authority
IS
Iceland
Prior art keywords
vaccine formulation
new vaccine
antigen
compositions
adjuvant
Prior art date
Application number
IS4518A
Other languages
English (en)
Inventor
Gizurarson Sveinbjörn
Guthmundsdottir Vera
Original Assignee
Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group filed Critical Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group
Priority to IS4518A priority Critical patent/IS4518A/is
Priority to PCT/IS1998/000006 priority patent/WO1999002186A2/en
Priority to JP2000501776A priority patent/JP2001509491A/ja
Priority to CA002295237A priority patent/CA2295237A1/en
Priority to DE69834921T priority patent/DE69834921T2/de
Priority to BR9810568-0A priority patent/BR9810568A/pt
Priority to AU84598/98A priority patent/AU745849B2/en
Priority to ES98935262T priority patent/ES2267189T3/es
Priority to AT98935262T priority patent/ATE329617T1/de
Priority to KR1020007000180A priority patent/KR20010021622A/ko
Priority to CNB988069660A priority patent/CN1202863C/zh
Priority to US09/112,684 priority patent/US6514503B1/en
Priority to EP98935262A priority patent/EP1003551B1/en
Publication of IS4518A publication Critical patent/IS4518A/is
Priority to IS5329A priority patent/IS5329A/is
Priority to US10/195,226 priority patent/US20030099659A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
IS4518A 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni IS4518A (is)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
ES98935262T ES2267189T3 (es) 1997-07-09 1998-07-09 Sistema de administracion de antigeno que comprende derivados de monoglicerido o de diglicerido como adyuvantes.
AT98935262T ATE329617T1 (de) 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
CA002295237A CA2295237A1 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
DE69834921T DE69834921T2 (de) 1997-07-09 1998-07-09 Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
BR9810568-0A BR9810568A (pt) 1997-07-09 1998-07-09 Composição, uso da mesma, e, processo para extrair uma imuno resposta para um antìgeno em um mamìfero, para fornecer um antìgeno para uma superfìcie mucósica de um mamìfero e para fornecer um agente bioativo para um vegetal
AU84598/98A AU745849B2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
PCT/IS1998/000006 WO1999002186A2 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
JP2000501776A JP2001509491A (ja) 1997-07-09 1998-07-09 アジュバントとしてモノグリセリドまたはジグリセリドを含む抗原送達系
KR1020007000180A KR20010021622A (ko) 1997-07-09 1998-07-09 보조제로서의 모노글리세리드 또는 디글리세리드 유도체를함유하는 항원 전달계
CNB988069660A CN1202863C (zh) 1997-07-09 1998-07-09 包含作为佐剂的甘油单酯或甘油二酯衍生物的抗原释放系统
US09/112,684 US6514503B1 (en) 1997-07-09 1998-07-09 Antigen delivery system
EP98935262A EP1003551B1 (en) 1997-07-09 1998-07-09 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
IS5329A IS5329A (is) 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar
US10/195,226 US20030099659A1 (en) 1997-07-09 2002-07-12 Antigen delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni

Publications (1)

Publication Number Publication Date
IS4518A true IS4518A (is) 1999-01-10

Family

ID=36699745

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4518A IS4518A (is) 1997-07-09 1997-07-09 Nýtt lyfjaform fyrir bóluefni
IS5329A IS5329A (is) 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS5329A IS5329A (is) 1997-07-09 1999-12-29 Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar

Country Status (13)

Country Link
US (2) US6514503B1 (is)
EP (1) EP1003551B1 (is)
JP (1) JP2001509491A (is)
KR (1) KR20010021622A (is)
CN (1) CN1202863C (is)
AT (1) ATE329617T1 (is)
AU (1) AU745849B2 (is)
BR (1) BR9810568A (is)
CA (1) CA2295237A1 (is)
DE (1) DE69834921T2 (is)
ES (1) ES2267189T3 (is)
IS (2) IS4518A (is)
WO (1) WO1999002186A2 (is)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
DE69937343T2 (de) * 1998-05-07 2008-07-24 Corixa Corp., Seattle Adjuvanszusammensetzung und methoden zu deren verwendung
WO2000069456A2 (en) 1999-05-13 2000-11-23 American Cyanamid Company Adjuvant combination formulations
DE69937580D1 (de) * 1999-08-18 2007-12-27 Ind Academic Coop Agent zur induktion einer immunologischen toleranz
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB0007465D0 (en) * 2000-03-29 2000-05-17 Amersham Pharm Biotech Uk Ltd Substrate for a lipase enzyme assay
IL153133A0 (en) * 2000-06-22 2003-06-24 American Cyanamid Co Qs-21 and il-12 as an adjuvant combination
PL366031A1 (en) * 2000-11-10 2005-01-24 Wyeth Holdings Corporation Adjuvant combination formulations
CN1541111A (zh) * 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
CN1977971A (zh) * 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
US20040241310A1 (en) * 2001-08-16 2004-12-02 Sveibjorn Gizurarson Method of producing antibodies ex-vivo
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
AU2003205979A1 (en) * 2002-02-25 2003-09-09 Lyfjathroun Hf, Biopharmaceutical Research An immunological adjuvant
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
WO2004046693A1 (ja) * 2002-11-21 2004-06-03 Sapporo Immuno Diagnostic Laboratory 唾液の採取および回収器具
AU2003299722A1 (en) * 2002-12-17 2004-07-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US8685718B2 (en) * 2003-05-20 2014-04-01 New York University Mucosal immunization to prevent prion infection
WO2005019412A2 (en) 2003-05-20 2005-03-03 New York University Mucosal immunization to prevent prion infection
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
US20060264505A1 (en) * 2003-11-07 2006-11-23 Stiefel Laboratories, Inc. Dermatological compositions
CN1909921B (zh) * 2003-11-10 2012-09-26 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
EP1917976B1 (en) 2005-08-01 2011-03-16 Hisamitsu Pharmaceutical Co. Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
JP5081243B2 (ja) * 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション 肺炎球菌抗原を被検体における肺炎球菌性肺炎の指標とする方法
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
EP2164957B1 (en) 2007-05-23 2017-07-12 The UAB Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
WO2010041143A2 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2010105047A2 (en) * 2009-03-11 2010-09-16 Monsanto Technology Llc Herbicidal formulations comprising glyphosate and alkoxylated glycerides
JP5762307B2 (ja) * 2009-03-31 2015-08-12 国立感染症研究所長 経鼻投与用ワクチンを用いるインフルエンザの予防方法
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6114401B2 (ja) 2013-10-31 2017-04-12 久光製薬株式会社 アジュバント組成物、これを含むアジュバント製剤、及びキット
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008517A2 (en) * 1996-08-26 1998-03-05 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
NL195510A (is) * 1955-03-11
FR2253499B1 (is) * 1973-12-10 1977-11-04 Fabre Sa Pierre
US4420484A (en) * 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
DE3225706C2 (de) 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS60149510A (ja) * 1984-01-13 1985-08-07 Kao Corp 農薬組成物
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4771571A (en) * 1986-12-31 1988-09-20 Nabisco Brands, Inc. Method for treating pineapple to prevent pineapple fruit diseases
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
EP0324455A3 (en) 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
GB9207799D0 (en) 1992-04-09 1992-05-27 Procter & Gamble Aqueous compositions
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU679013B2 (en) * 1992-10-16 1997-06-19 Ibah, Inc. Convertible microemulsion formulations
IT1255895B (it) * 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
AU6018894A (en) * 1993-01-15 1994-08-15 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DK0722323T3 (da) * 1994-08-05 2000-04-03 Inpharma Sa Præparater indeholdende troxerutin komplekseret med phosphatidylcholin til topisk behandling af erektil impotens
FR2729307B1 (fr) 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
EP0833621B1 (en) * 1995-06-09 2002-01-30 R.P. Scherer Technologies, Inc. Soft gelatin capsules containing particulate material
TW410158B (en) 1995-11-30 2000-11-01 Chemo Sero Therapeut Res Inst Oil adjuvant vaccine and method for preparing same
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
FR2773489B1 (fr) * 1998-01-15 2001-03-23 Immunotech Sa Nouvelle composition destinee a la voie oromuqueuse notamment pernasale
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent

Also Published As

Publication number Publication date
WO1999002186A2 (en) 1999-01-21
US20030099659A1 (en) 2003-05-29
JP2001509491A (ja) 2001-07-24
ES2267189T3 (es) 2007-03-01
DE69834921D1 (de) 2006-07-27
IS5329A (is) 1999-12-29
AU8459898A (en) 1999-02-08
CN1262626A (zh) 2000-08-09
KR20010021622A (ko) 2001-03-15
US6514503B1 (en) 2003-02-04
AU745849B2 (en) 2002-04-11
BR9810568A (pt) 2000-09-19
WO1999002186A3 (en) 1999-04-01
EP1003551A2 (en) 2000-05-31
DE69834921T2 (de) 2007-01-18
CA2295237A1 (en) 1999-01-21
ATE329617T1 (de) 2006-07-15
EP1003551B1 (en) 2006-06-14
CN1202863C (zh) 2005-05-25

Similar Documents

Publication Publication Date Title
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
NO20015073D0 (no) Vaksiner
WO2005037190A3 (en) Multiplex vaccines
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
EP2275122A3 (en) Protein-based streptococcus pneumoniae vaccines
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
NO20023935D0 (no) Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO2004058188A3 (en) Vaccine compositions and methods
MY127452A (en) Vaccines.
ATE329615T1 (de) Borrelia burgdorferi bacterin
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
HK1025220A1 (en) Novel saponin compositions and uses thereof
WO2004033483A3 (en) Liposomal system and method of using same
WO2002032455A3 (en) Vaccine
WO2002036160A3 (es) Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine